West Pharmaceutical Services (WST) EBITDA (2009 - 2026)

West Pharmaceutical Services has disclosed EBITDA across 18 years of filings, most recently posting $177.1 million for Q1 2026.

• EBITDA for Q1 2026 came in at $177.1 million, up 65.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $655.0 million (up 18.21% YoY), and the FY2025 annual result was $584.9 million, up 2.63% from the prior year.
• EBITDA came in at $177.1 million for Q1 2026 at West Pharmaceutical Services, up from $156.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $228.4 million in Q2 2022 to a low of $107.0 million in Q1 2025.
• The 5-year median for EBITDA is $160.9 million (2023), against an average of $161.3 million.
• Across the five-year window, EBITDA plunged 30.85% in 2024 and jumped 65.51% in 2026, its largest moves.
• West Pharmaceutical Services' EBITDA stood at $129.7 million in 2022, then advanced by 24.06% to $160.9 million in 2023, then fell by 0.81% to $159.6 million in 2024, then retreated by 1.88% to $156.6 million in 2025, then rose by 13.09% to $177.1 million in 2026.
• The last three EBITDA figures came in at $177.1 million (Q1 2026), $156.6 million (Q4 2025), and $167.6 million (Q3 2025), per Business Quant data.